Status:
COMPLETED
52-104 Week Off-therapy Second Extension to Study CSPP100A2365
Lead Sponsor:
Noden Pharma
Conditions:
Hypertension
Eligibility:
All Genders
6-17 years
Brief Summary
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2...
Eligibility Criteria
Inclusion
- Successful completion of study CSPP100A2365E1
- Patients must meet inclusion criteria set forth for trials CSPP100A2365 and CSPP100A2365E1
- Informed consent/ patient assent
Exclusion
- •Patients who did not successfully complete studies CSPP100A2365 and CSPP100A2365E1
Key Trial Info
Start Date :
August 19 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 3 2017
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT01420068
Start Date
August 19 2011
End Date
August 3 2017
Last Update
March 19 2019
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Birmingham, Alabama, United States, 35294-0006
2
Novartis Investigative Site
Little Rock, Arkansas, United States, 72202
3
Novartis Investigative Site
Dalton, Georgia, United States, 30721
4
Novartis Investigative Site
Lewiston, Idaho, United States, 83501